Back
Corporate News
Concord Biotech acquires 75% stake in Stellon Biotech
02-Jul-2025, 12:10
Concord Biotech has made an equity investment of USD 1,500 in Stellon Biotech Inc. This investment represents the subscription of 15 million equity shares at a price of USD 0.0001 per share resulting into 75% ownership in Stellon Biotech Inc to expand Company's business operations in USA.
Concord Biotech has made an equity investment of USD 1,500 in Stellon Biotech Inc. This investment represents the subscription of 15 million equity shares at a price of USD 0.0001 per share resulting into 75% ownership in Stellon Biotech Inc to expand Company's business operations in USA.
Stellon Biotech Inc. is a Delaware-incorporated pharmaceutical company established in December 2024. As a newly formed entity, Stellon is currently in its pre-revenue phase and was specifically created to support the marketing and commercialization of products developed by Concord Biotech.
Powered by Capital Market - Live News